AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19951554 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 19951554 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 400 mg group
Number of subjects: 29
Study 17530931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity/high volume (LIHV) isokinetic resistance exercise
Number of subjects: 10
Study 17530931 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity/low volume (HILV) isokinetic resistance exercise
Number of subjects: 10
Study 15199365 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARalpha polymorphism L162V in patients with DM‐2
Number of subjects: 842
Study 15199365 — intervention group
Group type: COMPARATOR
Intervention: PPARalpha polymorphism L162V in nondiabetic controls
Number of subjects: 842
Study 11777990 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0
Study 9658293 — intervention group
Group type: EXPERIMENTAL
Intervention: Candela laser lithotripsy
Number of subjects: 24
Study 9658293 — intervention group
Group type: COMPARATOR
Intervention: Electrohydraulic lithotripsy (EHL)
Number of subjects: 24
Study 7653447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/day, for > or = 5 years
Number of subjects: 9014
Study 7653447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 2644748 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg.kg‐1)
Number of subjects: 59
Study 2644748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg.kg‐1)
Number of subjects: 59
Study 2644748 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.1 mg.kg‐1) - up to 8 incremental doses
Number of subjects: 59
Study 2644748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.015 mg.kg‐1) - maximum of 4 increments
Number of subjects: 59
Study 2644748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 59
Study 2644748 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 59
Study 729619 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Number of subjects: 33
Study 729619 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Number of subjects: 33
Study 729619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 33
Study 31910395 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed technique (ST)
Number of subjects: 50
Study 31910395 — intervention group
Group type: COMPARATOR
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 50
Study 31910395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ST and EMS
Number of subjects: 50
Study 31450171 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 480
Study 31450171 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2/week)
Number of subjects: 480
Study 31450171 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 480
Study 31450171 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 480
Study 27634384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 1319
Study 27634384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1319
Study 26347398 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP at 300mmHg (full pressure)
Number of subjects: 23
Study 26347398 — intervention group
Group type: COMPARATOR
Intervention: ECP at 75mmHg (sham pressure)
Number of subjects: 23
Study 26347398 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP (both groups)
Number of subjects: 23
Study 22741619 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200 mg/day)
Number of subjects: 14
Study 22741619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21275922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) treatment during the active hormone phase (OC phase)
Number of subjects: 15
Study 21275922 — intervention group
Group type: COMPARATOR
Intervention: Non-OC phase (hormone-free phase)
Number of subjects: 15
Study 19111408 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR2 G‐G‐G haplotype (major allele for all polymorphisms)
Number of subjects: 561
Study 19111408 — intervention group
Group type: COMPARATOR
Intervention: Polymorphisms rs1271572, rs1256049, rs4986938
Number of subjects: 561
Study 17513689 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Blood drawn without a tourniquet, sample placed in ice (‐1 degrees C)
Number of subjects: 80
Study 17513689 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Blood drawn without a tourniquet, sample left at 23 degrees C
Number of subjects: 80
Study 17513689 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Blood drawn with a tourniquet placed 5 minutes before venipuncture, sample placed in ice (‐1 degrees C)
Number of subjects: 80
Study 17513689 — intervention group
Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 80
Study 17513689 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 80
Study 17513689 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 80
Study 15310737 — intervention group
Group type: EXPERIMENTAL
Intervention: 19% dietary fat intake
Number of subjects: 11
Study 15310737 — intervention group
Group type: COMPARATOR
Intervention: 30% dietary fat intake
Number of subjects: 11
Study 15310737 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dietary fat intake
Number of subjects: 11
Study 11455373 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive ibuprofen therapy (400 mg taken orally 1 hour before separator placement and 400 mg taken orally 6 hours after the initial dose)
Number of subjects: 41
Study 11455373 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ibuprofen therapy (400 mg taken orally 1 hour before separator placement and a lactose capsule taken orally 6 hours after the initial dose)
Number of subjects: 41
Study 11455373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preemptive and postoperative ibuprofen therapy (lactose capsule taken orally 1 hour before separator placement and 400 mg ibuprofen taken 6 hours after the initial placebo)
Number of subjects: 41
Study 11455373 — intervention group
Group type: COMPARATOR
Intervention: Lactose capsule (control group)
Number of subjects: 41
Study 9926482 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 200
Study 9926482 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 200
Study 7509219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate
Number of subjects: 0
Study 7509219 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 0
Study 3053941 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tabs daily for 6 weeks)
Number of subjects: 30
Study 31623964 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion condition (virtual ball tossing game)
Number of subjects: 84
Study 31623964 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated social exclusion experiences
Number of subjects: 84
Study 30234397 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Healthcare Interactive Virtual Simulation Training System (HH‐VSTS)
Number of subjects: 74
Study 30234397 — intervention group
Group type: COMPARATOR
Intervention: Paper-based training group
Number of subjects: 74
Study 28240635 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-bolus protocol
Number of subjects: 60
Study 28240635 — intervention group
Group type: COMPARATOR
Intervention: Bolus-tracking protocol
Number of subjects: 60
Study 25926145 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileMums intervention (12-week programme with personalised SMS text messages)
Number of subjects: 36000
Study 25926145 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36000
Study 23778346 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) applied before the second treadmill test in Group A
Number of subjects: 52
Study 23778346 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) applied before the first treadmill test in Group B
Number of subjects: 52
Study 23778346 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) with no RIPC applied
Number of subjects: 52
Study 21960071 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery (OPCAB)
Number of subjects: 304
Study 21960071 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass surgery
Number of subjects: 304
Study 19608797 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (40 mg)
Number of subjects: 90
Study 19608797 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (600 mug)
Number of subjects: 90
Study 18236783 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccoadhesive film containing 30 mg of ketorolac tromethamine (KT)
Number of subjects: 0
Study 18236783 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 15219660 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic breast cancer patients
Number of subjects: 17
Study 15219660 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 17
Study 11887473 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse periodontal health status
Number of subjects: 0
Study 9695137 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 1 microgram/kg
Number of subjects: 10
Study 9695137 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-syntropin (ACTH1-24) 0.25 mg
Number of subjects: 10
Study 9695137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7974335 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII CPS‐P (pasteurised concentrate)
Number of subjects: 44
Study 7974335 — intervention group
Group type: COMPARATOR
Intervention: Low dose factor VIII (immune tolerance therapy)
Number of subjects: 44
Study 7974335 — intervention group
Group type: EXPERIMENTAL
Intervention: Another concentrate (after switching from CPS‐P)
Number of subjects: 44
Study 2686075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2-interferon (injected intramuscularly for 10 days)
Number of subjects: 0
Study 10746 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 54
Study 10746 — intervention group
Group type: COMPARATOR
Intervention: Thorazine
Number of subjects: 54
Study 30893694 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC matrix for milk
Number of subjects: 7
Study 30893694 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC matrix for raw egg
Number of subjects: 7
Study 30893694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory test for blinding of egg and milk
Number of subjects: 7
Study 30893694 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological analysis of matrices
Number of subjects: 7
Study 30646047 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care plus chiropractic care
Number of subjects: 750
Study 30646047 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care alone
Number of subjects: 750
Study 26238463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a
Number of subjects: 140
Study 26238463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 25358867 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable paliperidone palmitate (PP)
Number of subjects: 3557
Study 25358867 — intervention group
Group type: COMPARATOR
Intervention: Oral paliperidone extended release (Pali ER)
Number of subjects: 3557
Study 22065105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous interferential (IF) electrical stimulation
Number of subjects: 30
Study 22065105 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 20598010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 66
Study 20598010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17906567 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 30 microg/kg rFVIIa
Number of subjects: 49
Study 17906567 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 60 microg/kg rFVIIa
Number of subjects: 49
Study 17906567 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 120 microg/kg rFVIIa
Number of subjects: 49
Study 17906567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16287344 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g Cr + 18 g dextrose + 4 g of sodium and potassium phosphates (CrP)
Number of subjects: 61
Study 16287344 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g Cr + 20 g dextrose (Cr)
Number of subjects: 61
Study 16287344 — intervention group
Group type: COMPARATOR
Intervention: 18 g dextrose as placebo (PL)
Number of subjects: 61
Study 12118486 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous metallic mitral valvuloplasty using a metallic valvulotome
Number of subjects: 57
Study 12118486 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous metallic mitral valvulotomy using a metallic valvulotome
Number of subjects: 57
Study 9893070 — intervention group
Group type: EXPERIMENTAL
Intervention: FIXED% method (20-25% vertebral height reduction criterion)
Number of subjects: 7238
Study 9893070 — intervention group
Group type: EXPERIMENTAL
Intervention: Various morphometric approaches to defining incident deformities
Number of subjects: 7238
Study 8626880 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine once at night
Number of subjects: 12
Study 8626880 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine twice daily (morning and evening)
Number of subjects: 12
Study 8626880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2252999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy (breast conservation)
Number of subjects: 119
Study 2252999 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 119
Study 6119943 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral alimentation
Number of subjects: 16
Study 30579992 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation and three times aminolaevulinic acid-based photodynamic therapy (ALA-PDT)
Number of subjects: 100
Study 28551698 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated night shift
Number of subjects: 12
Study 28551698 — intervention group
Group type: COMPARATOR
Intervention: Simulated day shift
Number of subjects: 12
Study 26246087 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bacillus clausii)
Number of subjects: 244
Study 26246087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 22759488 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 38
Study 22759488 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regional anaesthesia
Number of subjects: 38
Study 21551507 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 65
Study 21551507 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ)
Number of subjects: 65
Study 21551507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 19958629 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd‐p53 injection combined with cisplatin
Number of subjects: 35
Study 17966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-EMS Sigma Pharma 875 mg
Number of subjects: 20
Study 17966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxil BD 875 mg
Number of subjects: 20
Study 15136603 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 10
Study 15136603 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone group
Number of subjects: 10
Study 15136603 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 10
Study 11440291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID for 5 days
Number of subjects: 16
Study 11440291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID coadministered with digoxin (375 microg once daily)
Number of subjects: 16
Study 11440291 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (375 microg once daily)
Number of subjects: 16
Study 11440291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID
Number of subjects: 16
Study 9505774 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cm H2O)
Number of subjects: 89
Study 9505774 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (control)
Number of subjects: 89
Study 8055124 — intervention group
Group type: EXPERIMENTAL
Intervention: $1 incentive with first mailing
Number of subjects: 8356
Study 8055124 — intervention group
Group type: EXPERIMENTAL
Intervention: $1 incentive with second mailing
Number of subjects: 8356
Study 8055124 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 8356
Study 3671257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 20
Study 3671257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study 29351650 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) energy balance intervention
Number of subjects: 900
Study 26806546 — intervention group
Group type: EXPERIMENTAL
Intervention: ViveSoy® (500 mL per day, 15 g of protein, 50 mg of isoflavones)
Number of subjects: 147
Study 26516121 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2495655 (LY) 315 mg
Number of subjects: 201
Study 26516121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 26516121 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2495655 (LY)
Number of subjects: 201
Study 22903446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with meridian acupoints and three Anmian acupoints (Group B)
Number of subjects: 60
Study 22903446 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture with meridian acupoints (Group A)
Number of subjects: 60
Study 16413878 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (12.5 mg) and folic acid (50 microg)
Number of subjects: 25490
Study 16413878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc alone (10 mg)
Number of subjects: 25490
Study 16413878 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron, folic acid, and zinc
Number of subjects: 25490
Study 16413878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25490
Study 16413878 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (with or without zinc)
Number of subjects: 25490
Study 12794395 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg rPAF‐AH
Number of subjects: 127
Study 12794395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg rPAF‐AH
Number of subjects: 127
Study 12794395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 10343209 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 100
Study 10343209 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 100
Study 8541002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 mg/day)
Number of subjects: 122
Study 8541002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 1850208 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly psychotherapy, family therapy, or group therapy led by paraprofessionals
Number of subjects: 168
Study 7140566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1,000 mg/d)
Number of subjects: 18
Study 7140566 — intervention group
Group type: COMPARATOR
Intervention: Antacids (magnesium-aluminium hydroxide, neutralization capacity 564 mmol/d)
Number of subjects: 18
Study 7140566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily)
Number of subjects: 18
Study 31957666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU intramuscular injection)
Number of subjects: 90
Study 31957666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study 31708410 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 0
Study 31708410 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 0
Study 31708410 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab dose increase to 150 mg Q2W
Number of subjects: 0
Study 31708410 — intervention group
Group type: COMPARATOR
Intervention: Background statin therapy
Number of subjects: 0
Study 28844193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with dabigatran (110 mg twice daily)
Number of subjects: 2725
Study 28844193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with dabigatran (150 mg twice daily)
Number of subjects: 2725
Study 28844193 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with warfarin, P2Y12 inhibitor, and aspirin
Number of subjects: 2725
Study 28844193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with dabigatran (both doses combined)
Number of subjects: 2725
Study 26004431 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (dosage not specified)
Number of subjects: 220
Study 23360409 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to cervical and breast cancer screening
Number of subjects: 32
Study 23360409 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators to cervical and breast cancer screening
Number of subjects: 32
Study 23360409 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about screening needs
Number of subjects: 32
Study 21221528 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for depression (SCR)
Number of subjects: 223
Study 21221528 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 223
Study 19104789 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 14 days)
Number of subjects: 200